Pembrolizumab,Belzutifan,cabozantinib
Merck
['triplet,(-triplete)', 'belzutifan', 'cabozantinib', 'renal,(-adrenal)']
belzutifan and cabozantinib (n=50) pts with 1st line advanced renal cancer. 60% good risk. rr= 57% which is impressive. dfs and os probably influenced by good risk group . 37% g3/4 tox. this is promising but will need to be combined with pd1- a different triplet #esmo22 
Interested in Urology Cancers, biomarkers and drug development.